1159825-32-7 Usage
Uses
Used in Pharmaceutical Industry:
4-Formylpiperidine HCl is used as a chemical intermediate for the synthesis of various pharmaceutical compounds. Its unique structure allows it to be a key component in the development of new drugs, potentially contributing to the creation of innovative therapeutic agents.
Used in Organic Synthesis:
In the field of organic chemistry, 4-Formylpiperidine HCl is utilized as a versatile intermediate. Its reactivity and functional groups make it suitable for a range of chemical reactions, facilitating the synthesis of complex organic molecules for various applications.
Used in Research and Development:
4-Formylpiperidine HCl is also used as a subject of study in research and development. Its distinctive properties and structure make it an interesting target for scientists exploring new methods of synthesis, potential applications, and the underlying chemistry of heterocyclic compounds.
Check Digit Verification of cas no
The CAS Registry Mumber 1159825-32-7 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,1,5,9,8,2 and 5 respectively; the second part has 2 digits, 3 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 1159825-32:
(9*1)+(8*1)+(7*5)+(6*9)+(5*8)+(4*2)+(3*5)+(2*3)+(1*2)=177
177 % 10 = 7
So 1159825-32-7 is a valid CAS Registry Number.
1159825-32-7Relevant articles and documents
METHODS FOR HAIR FOLLICLE STEM CELL PROLIFERATION
-
Paragraph 0457-0458, (2020/05/06)
The present invention relates to compositions of minoxidil and Sonic Hedgehog (Shh) pathway activators and optionally, Wnt agonists and methods of using them to induce self-renewal of hair follicle stem cells, including inducing the hair follicle stem cells to proliferate while maintaining, in the daughter cells, the capacity to differentiate into hair follicle epithelial cells.
NOVEL COMPOUNDS HAVING ESTROGEN RECEPTOR ALPHA DEGRADATION ACTIVITY AND USES THEREOF
-
Paragraph 0563, (2020/06/08)
The present disclosure relates to novel compounds having estrogen receptor alpha degradation activity, pharmaceutical compositions containing such compounds, and their use in prevention and treatment of cancer and related diseases and conditions.